↓ Skip to main content

Dove Medical Press

Article Metrics

5-HTP efficacy and contraindications

Overview of attention for article published in Neuropsychiatric Disease and Treatment, July 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
41 tweeters
facebook
5 Facebook pages
wikipedia
3 Wikipedia pages
googleplus
1 Google+ user
reddit
2 Redditors
video
2 video uploaders

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
199 Mendeley
Title
5-HTP efficacy and contraindications
Published in
Neuropsychiatric Disease and Treatment, July 2012
DOI 10.2147/ndt.s33259
Pubmed ID
Authors

Marty Hinz, Alvin Stein, Marty Hinz

Abstract

L-5-hydroxytryptophan (5-HTP) is the immediate precursor of serotonin. It is readily synthesized into serotonin without biochemical feedback. This nutrient has a large and strong following who advocate exaggerated and inaccurate claims relating to its effectiveness in the treatment of depression and a number of other serotonin-related diseases. These assertions are not supported by the science. Under close examination, 5-HTP may be contraindicated for depression in some of the very patients for whom promoters of 5-HTP advocate its use.

Twitter Demographics

The data shown below were collected from the profiles of 41 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 199 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
United States 2 1%
Iran, Islamic Republic of 1 <1%
Netherlands 1 <1%
Unknown 193 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 64 32%
Student > Master 25 13%
Researcher 23 12%
Student > Postgraduate 18 9%
Other 17 9%
Other 23 12%
Unknown 29 15%
Readers by discipline Count As %
Medicine and Dentistry 50 25%
Nursing and Health Professions 25 13%
Biochemistry, Genetics and Molecular Biology 23 12%
Agricultural and Biological Sciences 17 9%
Psychology 12 6%
Other 39 20%
Unknown 33 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 62. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2021.
All research outputs
#459,710
of 19,152,115 outputs
Outputs from Neuropsychiatric Disease and Treatment
#52
of 2,766 outputs
Outputs of similar age
#2,473
of 138,515 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#1
of 32 outputs
Altmetric has tracked 19,152,115 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,766 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 138,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.